The application of CRISPR–Cas13 for targeted RNA degradation is hindered by the existence of collateral effects induced by Cas13. We screened hundreds of engineered Cas13 variants using a convenient and sensitive reporter system and obtained several variants with markedly reduced collateral activity and efficient on-target activity, suitable for in vivo applications.

中文翻译：

---

具有最小侧链 RNA 靶向的工程化 Cas13 变体

CRISPR-Cas13 在靶向 RNA 降解中的应用受到 Cas13 诱导的附带效应的阻碍。我们使用方便且灵敏的报告系统筛选了数百个工程化 Cas13 变体，并获得了几个具有显着降低的侧支活性和有效的靶向活性的变体，适用于体内应用。